Mediwound Ltd
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.2% | 86.5% | 87.8% | 91.2% | 84.5% | 84.5% | 81.3% | 76.5% | 83.5% | 85.1% | 78.1% | 89.1% | 84.5% | |
| 18.8% | 13.5% | 12.2% | 8.8% | 15.5% | 15.5% | 18.7% | 23.5% | 16.5% | 14.9% | 21.9% | 10.9% | 15.5% | |
| 32.1% | 33.9% | 29.6% | 37.5% | 58.0% | 51.1% | 73.0% | 61.2% | 63.8% | 239.9% | 351.5% | 190.8% | 160.4% | |
| 29.6% | 126.8% | 34.1% | 35.7% | 49.9% | 69.2% | 45.2% | 36.9% | 42.7% | 205.9% | 155.9% | 125.9% | 104.2% | |
| 82.1% | 86.4% | 87.4% | 97.4% | 132.2% | 119.6% | 150.8% | 123.7% | 136.7% | 433.4% | 562.9% | 316.8% | 283.3% | |
| -63.3% | -72.9% | -75.2% | -88.6% | -116.7% | -104.2% | -132.1% | -100.1% | -120.2% | -418.5% | -541.0% | -305.9% | -267.9% | |
| – | 111.9% | 120.3% | 47.5% | 118.9% | – | – | 140.0% | – | – | – | 36.3% | – | |
| -45.0% | -30.4% | -195.5% | -124.6% | -235.6% | -66.6% | -18.2% | -232.7% | -47.9% | -380.8% | -201.3% | -238.0% | -168.9% | |
| 1.0% | 2.2% | 0.5% | 0.0% | 0.5% | 0.3% | 0.1% | 0.7% | 1.0% | 3.9% | -1.2% | 1.1% | 1.2% | |
| -46.0% | -32.7% | -196.0% | -124.5% | -236.1% | -66.9% | -18.4% | -233.3% | -48.8% | -384.7% | -200.1% | -239.1% | -170.1% | |
| -37.9% | 105.6% | -67.8% | -70.0% | -108.4% | -269.1% | -9.2% | -85.7% | -40.2% | -277.1% | -175.7% | -292.9% | -160.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.